Boris N Kholodenko
Biochemistry — University College Dublin, Ireland
Boris N Kholodenko
LeadR Profile
Biochemistry
Subspecialties: Oncology - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1992 - 2026
Number : 228
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Polycomb Repressive Complex 2 drives flow-sensitive endothelial states underlying vascular inflammation and disease. polycomb repressive complex 2, genes, atherosclerosis, therapeutics, endothelium | Proc Natl Acad Sci U S A | 2026 | 0 |
| A structure-based modeling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia. genes, ras, pharmaceutical preparations, drug combinations, leukemia, leukemia, myeloid, acute, leukemia, myeloid | iScience | 2026 | 0 |
| IFN γ and IFN γ mimetics prevent IFN-I-mediated TB susceptibility by regulating iron metabolism and lipid peroxidation. macrophage activation, macrophages, pathology, tretinoin | bioRxiv | 2026 | 0 |
| Dual RAF inhibition outperforms RAF-MEK combinations for suppressing ERK signaling in KRAS mutant cells. cells, neoplasms | NPJ Syst Biol Appl | 2026 | 0 |
| Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer. pilots, pancreatic neoplasms, genes, ras, anemia, neoplasms, sorafenib, exanthema, drug-related side effects and adverse reactions, therapeutics, mutation, vemurafenib, plasma | J Immunother Precis Oncol | 2026 | 0 |
LeadR Networks
Main global connection map